Blue Water Vaccines, Inc. (BWV)
$0.2455
-0.02 (-9.07%)
Rating:
Recommendation:
-
| Symbol | BWV |
|---|---|
| Price | $0.2455 |
| Beta | 0.000 |
| Volume Avg. | 0.12M |
| Market Cap | 4.375M |
| Shares () | - |
| 52 Week Range | 0.181-1.95 |
| 1y Target Est | - |
| DCF Unlevered | BWV DCF -> | |
|---|---|---|
| DCF Levered | BWV LDCF -> | |
| ROE | -111.44% | Strong Sell |
| ROA | -65.34% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 126.22% | Buy |
| P/E | -0.23 | Neutral |
| P/B | 0.42 | Neutral |
Latest BWV news
About
Download (Excel)Dr. Neil J. Campbell MA, MBA
Healthcare
Biotechnology
NASDAQ Capital Market
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.